Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

p73 regulates epidermal wound healing and induced keratinocyte programming.

Beeler JS, Marshall CB, Gonzalez-Ericsson PI, Shaver TM, Santos Guasch GL, Lea ST, Johnson KN, Jin H, Venters BJ, Sanders ME, Pietenpol JA.

PLoS One. 2019 Jun 19;14(6):e0218458. doi: 10.1371/journal.pone.0218458. eCollection 2019.

2.

Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Sep;17(9):1842-1853. doi: 10.1158/1541-7786.MCR-19-0257. Epub 2019 Jun 11.

PMID:
31186280
3.

p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton.

Fuertes-Alvarez S, Maeso-Alonso L, Villoch-Fernandez J, Wildung M, Martin-Lopez M, Marshall C, Villena-Cortes AJ, Diez-Prieto I, Pietenpol JA, Tissir F, Lizé M, Marques MM, Marin MC.

Cell Death Dis. 2018 Dec 5;9(12):1183. doi: 10.1038/s41419-018-1205-6.

4.

p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion.

Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA.

iScience. 2018 Oct 26;8:236-249. doi: 10.1016/j.isci.2018.09.018. Epub 2018 Sep 25.

5.

Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.

Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD.

BMC Cancer. 2017 Apr 4;17(1):241. doi: 10.1186/s12885-017-3237-1.

6.

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.

7.

Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.

Cowen SD, Russell D, Dakin LA, Chen H, Larsen NA, Godin R, Throner S, Zheng X, Molina A, Wu J, Cheung T, Howard T, Garcia-Arenas R, Keen N, Pendleton CS, Pietenpol JA, Ferguson AD.

J Med Chem. 2016 Dec 22;59(24):11079-11097. Epub 2016 Dec 1.

PMID:
28002961
8.

Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O'Doherty GA, Lannigan DA.

Mol Cancer Ther. 2016 Nov;15(11):2598-2608. Epub 2016 Aug 15.

9.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.

PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

10.

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.

Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA.

Cancer Res. 2016 Aug 15;76(16):4850-60. doi: 10.1158/0008-5472.CAN-16-0058. Epub 2016 May 26.

11.

Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS.

BMC Cancer. 2016 Apr 18;16:275. doi: 10.1186/s12885-016-2307-0. No abstract available.

12.

p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network.

Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA.

Cell Rep. 2016 Mar 15;14(10):2289-300. doi: 10.1016/j.celrep.2016.02.035. Epub 2016 Mar 3.

13.

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS.

BMC Cancer. 2016 Feb 23;16:143. doi: 10.1186/s12885-016-2198-0. Erratum in: BMC Cancer. 2016;16(1):275.

14.

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM.

Cancer Discov. 2015 Nov;5(11):1155-63. doi: 10.1158/2159-8290.CD-15-0654. Epub 2015 Aug 18.

15.

Clinical implications of molecular heterogeneity in triple negative breast cancer.

Lehmann BD, Pietenpol JA.

Breast. 2015 Nov;24 Suppl 2:S36-40. doi: 10.1016/j.breast.2015.07.009. Epub 2015 Aug 5. Review.

16.

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

Lehmann BD, Pietenpol JA, Tan AR.

Am Soc Clin Oncol Educ Book. 2015:e31-9. doi: 10.14694/EdBook_AM.2015.35.e31.

17.

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.

Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D.

Oncotarget. 2015 Aug 28;6(25):21353-68.

18.

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.

Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D.

PLoS One. 2015 May 12;10(5):e0125482. doi: 10.1371/journal.pone.0125482. eCollection 2015.

19.

Detection of internal exon deletion with exon Del.

Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y.

BMC Bioinformatics. 2014 Oct 16;15:332. doi: 10.1186/1471-2105-15-332.

20.

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.

Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.

Breast Cancer Res. 2014 Aug 8;16(4):406. doi: 10.1186/s13058-014-0406-x.

21.

Subtyping of triple-negative breast cancer: implications for therapy.

Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA.

Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16. Review.

22.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

23.

Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.

Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK.

Cancer Res. 2014 Jun 1;74(11):3180-94. doi: 10.1158/0008-5472.CAN-13-3415. Epub 2014 Mar 24.

24.

New strategies for triple-negative breast cancer--deciphering the heterogeneity.

Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA.

Clin Cancer Res. 2014 Feb 15;20(4):782-90. doi: 10.1158/1078-0432.CCR-13-0583. Review.

25.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL.

Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19.

26.

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W.

Clin Cancer Res. 2013 Dec 15;19(24):6696-702. doi: 10.1158/1078-0432.CCR-13-1746.

27.

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.

Lehmann BD, Pietenpol JA.

J Pathol. 2014 Jan;232(2):142-50. doi: 10.1002/path.4280. Review.

28.

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT.

Clin Cancer Res. 2013 Oct 1;19(19):5533-40. doi: 10.1158/1078-0432.CCR-13-0799. Epub 2013 Aug 15.

29.

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC.

Clin Cancer Res. 2013 May 15;19(10):2723-33. doi: 10.1158/1078-0432.CCR-12-2986. Epub 2013 Apr 2.

30.

Patient-derived breast tumor xenografts facilitating personalized cancer therapy.

Landis MD, Lehmann BD, Pietenpol JA, Chang JC.

Breast Cancer Res. 2013 Jan 22;15(1):201. doi: 10.1186/bcr3355. Review.

31.

Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives.

Ye F, Bauer JA, Pietenpol JA, Shyr Y.

BMC Genomics. 2012;13 Suppl 8:S3. doi: 10.1186/1471-2164-13-S8-S3. Epub 2012 Dec 17.

32.

Targeting mutant p53 in human tumors.

Lehmann BD, Pietenpol JA.

J Clin Oncol. 2012 Oct 10;30(29):3648-50. doi: 10.1200/JCO.2012.44.0412. Epub 2012 Sep 10. Review. No abstract available.

PMID:
22965952
33.

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA.

Cancer Inform. 2012;11:147-56. doi: 10.4137/CIN.S9983. Epub 2012 Jul 24.

34.

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA.

J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.

35.

Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis.

Rosenbluth JM, Mays DJ, Jiang A, Shyr Y, Pietenpol JA.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2076-81. doi: 10.1073/pnas.1011936108. Epub 2011 Jan 18.

36.

Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation.

Barton CE, Johnson KN, Mays DM, Boehnke K, Shyr Y, Boukamp P, Pietenpol JA.

Cell Death Dis. 2010;1:e74. doi: 10.1038/cddis.2010.49.

37.

Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.

Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC.

Breast Cancer Res Treat. 2010 Dec;124(3):723-32. doi: 10.1007/s10549-010-1181-8. Epub 2010 Sep 29.

38.

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA.

Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24.

39.

ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy.

Eby KG, Rosenbluth JM, Mays DJ, Marshall CB, Barton CE, Sinha S, Johnson KN, Tang L, Pietenpol JA.

Mol Cancer. 2010 Apr 29;9:95. doi: 10.1186/1476-4598-9-95.

40.

Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.

Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA.

Clin Cancer Res. 2010 Jan 15;16(2):681-90. doi: 10.1158/1078-0432.CCR-09-1091. Epub 2010 Jan 12.

41.

Evaluation of p63 and p73 antibodies for cross-reactivity.

Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA.

Cell Cycle. 2009 Nov 15;8(22):3702-6. Epub 2009 Nov 9.

PMID:
19855172
42.

DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis.

Barton CE, Tahinci E, Barbieri CE, Johnson KN, Hanson AJ, Jernigan KK, Chen TW, Lee E, Pietenpol JA.

Dev Biol. 2009 May 1;329(1):130-9. doi: 10.1016/j.ydbio.2009.02.036. Epub 2009 Mar 6.

43.

mTOR regulates autophagy-associated genes downstream of p73.

Rosenbluth JM, Pietenpol JA.

Autophagy. 2009 Jan;5(1):114-6. Epub 2009 Jan 30.

44.

The jury is in: p73 is a tumor suppressor after all.

Rosenbluth JM, Pietenpol JA.

Genes Dev. 2008 Oct 1;22(19):2591-5. doi: 10.1101/gad.1727408. Review.

45.

Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1.

Brown KA, Ham AJ, Clark CN, Meller N, Law BK, Chytil A, Cheng N, Pietenpol JA, Moses HL.

J Cell Biochem. 2008 Oct 1;105(2):596-611. doi: 10.1002/jcb.21860.

46.

A gene signature-based approach identifies mTOR as a regulator of p73.

Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA.

Mol Cell Biol. 2008 Oct;28(19):5951-64. doi: 10.1128/MCB.00305-08. Epub 2008 Aug 4.

47.

Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes.

Burgess EF, Ham AJ, Tabb DL, Billheimer D, Roth BJ, Chang SS, Cookson MS, Hinton TJ, Cheek KL, Hill S, Pietenpol JA.

Proteomics Clin Appl. 2008 Jul 30;2(9):1223.

48.

p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm.

Perez CA, Ott J, Mays DJ, Pietenpol JA.

Oncogene. 2007 Nov 15;26(52):7363-70. Epub 2007 Jun 11.

PMID:
17563751
49.

Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.

Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N.

Cancer Biol Ther. 2007 Apr;6(4):561-70.

50.

p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis.

Schavolt KL, Pietenpol JA.

Oncogene. 2007 Sep 13;26(42):6125-32. Epub 2007 Apr 2.

PMID:
17404570

Supplemental Content

Loading ...
Support Center